Price$0.25-0.00 (-0.75%)
01:30 PM07:45 PM
News · 26 weeks42+267%
2026-03-012026-08-23
Mix2390d
- Other8(35%)
- SEC Filings7(30%)
- Insider3(13%)
- Dividends2(9%)
- Earnings2(9%)
- M&A1(4%)
Latest news
25 items- INSIDERPrincipal Accounting Officer Amman Bradford K. was granted 250,000 shares, increasing direct ownership by 312,500% to 250,080 units (SEC Form 4)4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- PRVivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine CentersLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week over week. The Company recently an
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and TreatmentNew Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees LITTLETON, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep disorders, today announced the official Grand Opening of its latest state-of-the-art diagnostic, te
- PRVivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdateQuarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company’’) (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, today reported financial results and operating highlights for the three and six months ended June 30, 2026. Kirk Huntsman, Vivos’ Chairman and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vivos Therapeutics Inc.SCHEDULE 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
- PRVivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference CallLITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company’’) (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, announced it plans to release its second quarter 2026 financial results after market close today, Friday, August 14, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue OperationsGreenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from revenue-cycle improvements In addition, Vivos expects to save $1.8 million annually from Greenway’s recovery of an estimated 46,000+ employee hours, while creating capacity for nearly 30,000 additional patient visits LITTLETON, Colo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalitie
- PRVivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device TechnologyLITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, today announced that the United States Patent and Trademark Office has issued US Patent No. 12,697,190 "Vibrational Oral Appliance with Mandibular Advancements" (the "’190 Patent"), a continuation of the Company’s previously issued US Patent No. 12,048,608 (the "’608 Patent"), issued July 30, 2024. Taken together, these two p
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- INSIDERSEC Form 4 filed by Large owner Skaff Michael C4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 3 filed by new insider V-Co Investors 4 Llc3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study ParticipantsLITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market. Newly Released Vida® Data Sup
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred EquityLITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea ("OSA"), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC ("Streeterville"). Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding deb
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingLITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea ("OSA"), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders. The Company currently expects to file a registration statement in connection with th
- PRVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsLITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA") and insomnia, today announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC ("SPCVA"), a growing Florida-based cardiology practice with approximately 30,000 patients of record, to support the formation and operation of AIM Florida, LLC ("AIM Florida"), a physician-aligned management services organization intended to expand
- PRVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City. Representing the Company, Kirk Hunstman, CEO, will deliver a corporate presentation at 11:30 am ET and will participate in one-on-one meetings with pre-qualified investors throughout the day. The Small C
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingLITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to $4.5 million of its outstanding debt into a combination of perpetual, nonconvertible preferred stock and shares of common stock of the Company. In addition, the agreement includes commitments from Streeterville to susp
- SECSEC Form 10-Q filed by Vivos Therapeutics Inc.10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateYear-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the first quarter ended March 31, 2026. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated "Our significant revenue increas
VVOS FAQ
7 questionsWhat does Vivos Therapeutics Inc. do?
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States...Where does VVOS stock trade?
Vivos Therapeutics Inc. (VVOS) is listed on NASDAQ.What sector and industry is VVOS in?
Vivos Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Vivos Therapeutics Inc. go public?
Vivos Therapeutics Inc. (VVOS) completed its IPO in 2020.What are analysts saying about VVOS?
Vivos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2021-08-13. Recent price targets cluster around $1000.00.What companies are similar to VVOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare VVOS side-by-side with any of them on Quantisnow.How can I track VVOS on Quantisnow?
Quantisnow aggregates Vivos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VVOS to receive live email and push alerts on every new disclosure.